Table 1 Demographics of patients with EoE that achieved histologic remission with PPI monotherapy in each phase of our study
| Â | Phase 1 | Phase 2 | ||
|---|---|---|---|---|
Characteristics | Patients with histologic remission of EoE on PPI monotherapy and trialed FED monotherapy (n = 22) | Patients with histologic remission of EoE on PPI monotherapy and FED monotherapy (n = 13) | Patients with histologic remission of EoE on PPI monotherapy and trialed FED monotherapy (n = 15) | Patients with istologic remission of EoE on PPI monotherapy and FED monotherapy (n = 9) |
Age, median (IQR) | 34 (29.2–39.7) | 37.9 (29.5–44) | 33.25 (29.3–46.3) | 38.4 (31.3–52.8) |
Male, n (%) | 13 (59.09%) | 8 (61.54%) | 10 (66.67%) | 6 (66.67%) |
Atopic comorbidity, n (%) | ||||
 Any atopic condition | 11 (50%) | 6 (46.15%) | 7 (46.67%) | 4 (44.44%) |
 Atopic dermatitis | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
 Asthma | 3 (13.64%) | 1 (7.69%) | 2 (13.33%) | 1 (11.11%) |
 Allergic rhinitis | 8 (36.36%) | 4 (30.77%) | 4 (26.67%) | 2 (22.22%) |
 Food allergy | 6 (27.27%) | 4 (30.77%) | 3 (20%) | 2 (22.22%) |
PPI monotherapy, n (%) | ||||
 Omeprazole 40 mg twice daily | 14 (63.64%) | 7 (53.85%) | 10 (66.67%) | 5 (55.56%) |
 Omeprazole 40 mg once daily | 7 (31.82%) | 5 (38.46%) | 4 (26.67%) | 3 (33.33%) |
 Omeprazole 20 mg twice daily | 1 (4.55%) | 1 (7.69%) | 1 (6.67%) | 1 (11.11%) |
FED monotherapy, n (%) | ||||
 Dairy, wheat, soy, egg, nut FED | 1 (4.55%) | 0 (0%) | 0 (0%) | 0 (0%) |
 4FED | 1 (4.55%) | 1 (7.69%) | 0 (0%) | 0 (0%) |
 Dairy, wheat, soy FED | 1 (4.55%) | 0 (0%) | 1 (6.67%) | 0 (0%) |
 2FED | 15 (68.18%) | 8 (61.54%) | 11 (73.33%) | 6 (66.67%) |
 Dairy FED | 4 (18.18%) | 4 (30.77%) | 3 (20%) | 3 (33.33%) |